Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12234296-B2
Publication Date
2025-02-25
Expiration Date
Abstract
The invention provides anti-βS globin antibodies or antigen binding fragments thereof.
Core Innovation
The invention relates to anti-b2S (sickled b2-globin) antibodies and antigen-binding fragments that bind a human b2S globin polypeptide. The antibody or antigen-binding fragment comprises a light chain variable region with CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3), and comprises a heavy chain variable region with CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6). The binding is described as recognizing the E6V (Glu6Val) b2S mutation.
The disclosed antigen-binding fragments include scFv formatting. The disclosure further includes nucleic acid and polynucleotide embodiments encoding the antibodies or antigen-binding fragments, including polynucleotides encoding the variable light chain and variable heavy chain components.
The invention also provides labeled conjugates formed by associating the anti-b2S antibody or antigen-binding fragment with detectable labels. The detectable labels are described as including fluorescent dyes/proteins, haptens, enzymes, and radionuclides, and the disclosure includes examples of antibody-fragment conjugate formats used for detecting HbS-specific staining.
Claims Coverage
The independent claim covers an anti-b2S globin antibody or antigen-binding fragment with defined light-chain and heavy-chain CDR1/2/3 sequence identities. The claim set includes dependent claim refinements that specify an scFv format, conjugates with detectable labels, selectable label types, and additional embodiments including a hybridoma producer and a polynucleotide encoding the antibody/fragment. Main inventive features are extracted below for each independent claim identified in the provided list.
CDR-defined anti-b2S globin binding
An anti-b2S globin antibody or antigen binding fragment thereof that binds a human b2S globin polypeptide, wherein the antibody or fragment comprises a light chain variable region comprising CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2), and CDR3 (SEQ ID NO: 3) and comprises a heavy chain variable region comprising CDR1 (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5), and CDR3 (SEQ ID NO: 6).
Across the provided independent claim, the core claim requires binding to a human b2S globin polypeptide with specific light-chain and heavy-chain CDR1/2/3 sequence identities (SEQ ID NOs 1-6), and the dependent claims further refine the claimed antibody/fragment into scFv formatting, detectable-label conjugates, and embodiments including hybridoma and encoding polynucleotides.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?